Stroke Risk Factors, Genetics, and Prevention

Circulation Research

Volumn 120, Issue 3, 2017, Pages 472-495

  Boehme, Amelia K ^a,b   Esenwa, Charles ^b   Elkind, Mitchell S V ^a,b  

^a Department of Medicine   (United States)

^b Columbia University ^*  (United States)

Author keywords

cerebrovascular disorders; epidemiology; risk factors; stroke; transient ischemic attack

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B;

AGE; ALCOHOL CONSUMPTION; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; DIABETES MELLITUS; DIET; DYSLIPIDEMIA; ETHNICITY; FRAMINGHAM RISK SCORE; GENETIC DISORDER; GENETIC POLYMORPHISM; GENETIC RISK; GENETICS; HEALTH BEHAVIOR; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; INFLAMMATION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; OBESITY; PHYSICAL INACTIVITY; POLLUTION; PREVENTION; PRIORITY JOURNAL; RACE; REVIEW; RISK FACTOR; RISK REDUCTION; SEX; SMOKING; SMOKING CESSATION; SUBSTANCE ABUSE; WAIST HIP RATIO; ADVERSE EFFECTS; CLINICAL TRIAL (TOPIC); GENETIC PREDISPOSITION; LIFESTYLE; PROCEDURES; STROKE;

BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; DIET; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; LIFE STYLE; RISK FACTORS; SMOKING; STROKE;

EID: 85011878933     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.308398     Document Type: Review

References (288)

1. Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart dis-ease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:e18-e209. doi: 10.1161/CIR.0b013e3182009701.
2. Mozzafarian D, Benjamin EJ, Go AS, et al, on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38-e360.
3. Ovbiagele B, Goldstein LB, Higashida RT, Howard VJ, Johnston SC, Khavjou OA, Lackland DT, Lichtman JH, Mohl S, Sacco RL, Saver JL, Trogdon JG; American Heart Association Advocacy Coordinating Committee and Stroke Council. Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association. Stroke. 2013;44:2361-2375. doi: 10.1161/STR.0b013e31829734f2.
4. Pearson TA, Palaniappan LP, Artinian NT, et al; American Heart Association Council on Epidemiology and Prevention. American Heart Association Guide for Improving Cardiovascular Health at the Community Level, 2013 update: a scientifc statement for public health practitioners, healthcare providers, and health policy makers. Circulation. 2013;127:1730-1753. doi: 10.1161/CIR.0b013e31828f8a94.
5. Mozaffarian D, Benjamin EJ, Go AS, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015;131:e29-322. doi: 10.1161/CIR.0000000000000152.
6. Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. 2007;6:611-619. doi: 10.1016/S1474-4422(07)70170-9.
7. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009;8:355-369. doi: 10.1016/S1474-4422(09)70025-0.
8. Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. Lancet Neurol. 2009;8:345-354. doi: 10.1016/S1474-4422(09)70023-7.
9. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classifcation of subtype of acute ischemic stroke. Defnitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
10. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology. 2004;63:1868-1875.
11. Zhao D, Liu J, Wang W, Zeng Z, Cheng J, Liu J, Sun J, Wu Z. Epidemiological transition of stroke in China: twenty-one-year ob-servational study from the Sino-MONICA-Beijing Project. Stroke. 2008;39:1668-1674. doi: 10.1161/STROKEAHA.107.502807.
12. Powers BJ, Danus S, Grubber JM, Olsen MK, Oddone EZ, Bosworth HB. The effectiveness of personalized coronary heart disease and stroke risk communication. Am Heart J. 2011;161:673-680. doi: 10.1016/j. ahj.2010.12.021.
13. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. AHA/ACC scientifc statement: assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 1999;34:1348-1359.
14. Pocock SJ, McCormack V, Gueyffer F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ. 2001;323:75-81.
15. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profle from the Framingham Study. Stroke. 1991;22:312-318.
16. Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA. 2012;308:796-803. doi: 10.1001/jama.2012.9630.
17. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profle: adjustment for antihypertensive medication. The Framingham Study. Stroke. 1994;25:40-43.
18. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, Larson MG, Kannel WB, Benjamin EJ. A risk score for predicting stroke or death in individuals with new-onset atrial fbrillation in the community: the Framingham Heart Study. JAMA. 2003;290:1049-1056. doi: 10.1001/jama.290.8.1049.
19. Lumley T, Kronmal RA, Cushman M, Manolio TA, Goldstein S. A stroke prediction score in the elderly: validation and Web-based application. J Clin Epidemiol. 2002;55:129-136.
20. Simons LA, McCallum J, Friedlander Y, Simons J. Risk factors for isch-emic stroke: Dubbo Study of the elderly. Stroke. 1998;29:1341-1346.
21. Chien KL, Su TC, Hsu HC, Chang WT, Chen PC, Sung FC, Chen MF, Lee YT. Constructing the prediction model for the risk of stroke in a Chinese population: report from a cohort study in Taiwan. Stroke. 2010;41:1858-1864. doi: 10.1161/STROKEAHA.110.586222.
22. Lackland DT, Elkind MS, D'Agostino R Sr, Dhamoon MS, Goff DC Jr, Higashida RT, McClure LA, Mitchell PH, Sacco RL, Sila CA, Smith SC Jr, Tanne D, Tirschwell DL, Touzé E, Wechsler LR; American Heart Association Stroke Council; Council on Epidemiology and Prevention; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research. Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:1998-2027. doi: 10.1161/STR.0b013e31825bcdac.
23. Yeboah J, Young R, McClelland RL, Delaney JC, Polonsky TS, Dawood FZ, Blaha MJ, Miedema MD, Sibley CT, Carr JJ, Burke GL, Goff DC Jr, Psaty BM, Greenland P, Herrington DM. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. J Am Coll Cardiol. 2016;67:139-147. doi: 10.1016/j.jacc.2015.10.058.
24. O'Donnell MJ, Xavier D, Liu L, et al; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112-123. doi: 10.1016/S0140-6736(10)60834-3.
25. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245. doi: 10.1161/CIR.0b013e31828124ad.
26. Elkind MS. Why now? Moving from stroke risk factors to stroke triggers. Curr Opin Neurol. 2007;20:51-57. doi: 10.1097/WCO.0b013e328012da75.
27. Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:188-197. doi: 10.1161/CIR.0b013e3182456d46.
28. Kissela BM, Khoury JC, Alwell K, Moomaw CJ, Woo D, Adeoye O, Flaherty ML, Khatri P, Ferioli S, De Los Rios La Rosa F, Broderick JP, Kleindorfer DO. Age at stroke: temporal trends in stroke incidence in a large, biracial population. Neurology. 2012;79:1781-1787. doi: 10.1212/WNL.0b013e318270401d.
29. George MG, Tong X, Kuklina EV, Labarthe DR. Trends in stroke hospi-talizations and associated risk factors among children and young adults, 1995-2008. Ann Neurol. 2011;70:713-721. doi: 10.1002/ana.22539.
30. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9:167-176. doi: 10.1016/S1474-4422(09)70340-0.
31. Kapral MK, Fang J, Hill MD, Silver F, Richards J, Jaigobin C, Cheung AM; Investigators of the Registry of the Canadian Stroke Network. Sex differences in stroke care and outcomes: results from the Registry of the Canadian Stroke Network. Stroke. 2005;36:809-814. doi: 10.1161/01. STR.0000157662.09551.e5.
32. Reeves MJ, Fonarow GC, Zhao X, Smith EE, Schwamm LH; Get With The Guidelines-Stroke Steering Committee & Investigators. Quality of care in women with ischemic stroke in the GWTG program. Stroke. 2009;40:1127-1133. doi: 10.1161/STROKEAHA.108.543157.
33. Asplund K, Karvanen J, Giampaoli S, et al; MORGAM Project. Relative risks for stroke by age, sex, and population based on follow-up of 18 European populations in the MORGAM Project. Stroke. 2009;40:2319-2326. doi: 10.1161/STROKEAHA.109.547869.
34. Cruz-Flores S, Rabinstein A, Biller J, Elkind MS, Griffth P, Gorelick PB, Howard G, Leira EC, Morgenstern LB, Ovbiagele B, Peterson E, Rosamond W, Trimble B, Valderrama AL; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council on Quality of Care and Outcomes Research. Racial-ethnic disparities in stroke care: the American experience: a statement for healthcare profes-sionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2091-2116. doi: 10.1161/STR.0b013e3182213e24.
35. Gillum RF. Stroke mortality in blacks. Disturbing trends. Stroke. 1999;30:1711-1715.
36. Howard G, Howard VJ; REasons for Geographic And Racial Differences in Stroke (REGARDS) Investigators. Ethnic disparities in stroke: the scope of the problem. Ethn Dis. 2001;11:761-768.
37. Kleindorfer D, Broderick J, Khoury J, Flaherty M, Woo D, Alwell K, Moomaw CJ, Schneider A, Miller R, Shukla R, Kissela B. The unchanging incidence and case-fatality of stroke in the 1990s: a population-based study. Stroke. 2006;37:2473-2478. doi: 10.1161/01.STR.0000242766.65550.92.
38. Cooper ES. Cardiovascular diseases and stroke in African Americans: a call for action. J Natl Med Assoc. 1993;85:97-100.
39. Kissela B, Schneider A, Kleindorfer D, Khoury J, Miller R, Alwell K, Woo D, Szafarski J, Gebel J, Moomaw C, Pancioli A, Jauch E, Shukla R, Broderick J. Stroke in a biracial population: the excess burden of stroke among blacks. Stroke. 2004;35:426-431. doi: 10.1161/01.STR.0000110982.74967.39.
40. Sacco RL, Boden-Albala B, Gan R, Chen X, Kargman DE, Shea S, Paik MC, Hauser WA. Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. Am J Epidemiol. 1998;147:259-268.
41. Howard G, Anderson R, Sorlie P, Andrews V, Backlund E, Burke GL. Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks. The National Longitudinal Mortality Study. Stroke. 1994;25:2120-2125.
42. Morgenstern LB, Smith MA, Lisabeth LD, Risser JM, Uchino K, Garcia N, Longwell PJ, McFarling DA, Akuwumi O, Al-Wabil A, Al-Senani F, Brown DL, Moyé LA. Excess stroke in Mexican Americans compared with non-Hispanic Whites: the Brain Attack Surveillance in Corpus Christi Project. Am J Epidemiol. 2004;160:376-383. doi: 10.1093/aje/kwh225.
43. Zahuranec DB, Brown DL, Lisabeth LD, Gonzales NR, Longwell PJ, Eden SV, Smith MA, Garcia NM, Morgenstern LB. Differences in intrace-rebral hemorrhage between Mexican Americans and non-Hispanic whites. Neurology. 2006;66:30-34. doi: 10.1212/01.wnl.0000191402.41914.d2.
44. Zhang Y, Galloway JM, Welty TK, Wiebers DO, Whisnant JP, Devereux RB, Kizer JR, Howard BV, Cowan LD, Yeh J, Howard WJ, Wang W, Best L, Lee ET. Incidence and risk factors for stroke in American Indians: the Strong Heart Study. Circulation. 2008;118:1577-1584. doi: 10.1161/CIRCULATIONAHA.108.772285.
45. Giles WH, Kittner SJ, Hebel JR, Losonczy KG, Sherwin RW. Determinants of black-white differences in the risk of cerebral infarction. The National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Arch Intern Med. 1995;155:1319-1324.
46. Gillum RF. Risk factors for stroke in blacks: a critical review. Am J Epidemiol. 1999;150:1266-1274.
47. Kittner SJ, White LR, Losonczy KG, Wolf PA, Hebel JR. Black-white differences in stroke incidence in a national sample. The contribution of hypertension and diabetes mellitus. JAMA. 1990;264:1267-1270.
48. Liao Y, Greenlund KJ, Croft JB, Keenan NL, Giles WH. Factors explaining excess stroke prevalence in the US Stroke Belt. Stroke. 2009;40:3336-3341. doi: 10.1161/STROKEAHA.109.561688.
49. Feinstein M, Ning H, Kang J, Bertoni A, Carnethon M, Lloyd-Jones DM. Racial differences in risks for frst cardiovascular events and noncardiovascular death: the Atherosclerosis Risk in Communities study, the Cardiovascular Health Study, and the Multi-Ethnic Study of Atherosclerosis. Circulation. 2012;126:50-59. doi: 10.1161/CIRCULATIONAHA.111.057232.
50. Glasser SP, Judd S, Basile J, Lackland D, Halanych J, Cushman M, Prineas R, Howard V, Howard G. Prehypertension, racial prevalence and its association with risk factors: analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Am J Hypertens. 2011;24:194-199. doi: 10.1038/ajh.2010.204.
51. Howard G, Safford MM, Moy CS, Howard VJ, Kleindorfer DO, Unverzagt FW, et al. Racial differences in the incidence of cardiovascular risk factors in older black and white adults [published online ahead of print September 26, 2016]. J Am Geriatr Soc. doi: 10.1111/jgs.14472.
52. Howard VJ, Kleindorfer DO, Judd SE, McClure LA, Safford MM, Rhodes JD, Cushman M, Moy CS, Soliman EZ, Kissela BM, Howard G. Disparities in stroke incidence contributing to disparities in stroke mortality. Ann Neurol. 2011;69:619-627. doi: 10.1002/ana.22385.
53. Joubert J, Prentice LF, Moulin T, Liaw ST, Joubert LB, Preux PM, Ware D, Medeiros de Bustos E, McLean A. Stroke in rural areas and small communities. Stroke. 2008;39:1920-1928. doi: 10.1161/STROKEAHA.107.501643.
54. Stansbury JP, Jia H, Williams LS, Vogel WB, Duncan PW. Ethnic disparities in stroke: epidemiology, acute care, and postacute outcomes. Stroke. 2005;36:374-386. doi: 10.1161/01.STR.0000153065.39325.fd.
55. Kimball MM, Neal D, Waters MF, Hoh BL. Race and income disparity in ischemic stroke care: nationwide inpatient sample database, 2002 to 2008. J Stroke Cerebrovasc Dis. 2014;23:17-24. doi: 10.1016/j. jstrokecerebrovasdis.2012.06.004.
56. Jabłecki J, Kaczmarzyk L, Domanasiewicz A, Paruzel M. [Management of soft tissue defects in the region of fnger PIP joints by means of pedicular skin faps taken from abdomen]. Chir Narzadow Ruchu Ortop Pol. 2006;71:205-209.
57. Greer S, Casper M, Kramer M, Schwartz G, Hallisey E, Holt J, Clarkson L, Zhou Y, Freymann G. Racial residential segregation and stroke mortality in Atlanta. Ethn Dis. 2011;21:437-443.
58. Kleindorfer D, Lindsell C, Alwell KA, Moomaw CJ, Woo D, Flaherty ML, Khatri P, Adeoye O, Ferioli S, Kissela BM. Patients living in impoverished areas have more severe ischemic strokes. Stroke. 2012;43:2055-2059. doi: 10.1161/STROKEAHA.111.649608.
59. Moon JR, Capistrant BD, Kawachi I, Avendaño M, Subramanian SV, Bates LM, Glymour MM. Stroke incidence in older US Hispanics: is foreign birth protective? Stroke. 2012;43:1224-1229. doi: 10.1161/STROKEAHA.111.643700.
60. Howard G, Moy CS, Howard VJ, McClure LA, Kleindorfer DO, Kissela BM, Judd SE, Unverzagt FW, Soliman EZ, Safford MM, Cushman M, Flaherty ML, Wadley VG; REGARDS Investigators∗. Where to focus efforts to reduce the black-white disparity in stroke mortality: inci-dence versus case fatality? Stroke. 2016;47:1893-1898. doi: 10.1161/STROKEAHA.115.012631.
61. Howard G, Kissela BM, Kleindorfer DO, McClure LA, Soliman EZ, Judd SE, Rhodes JD, Cushman M, Moy CS, Sands KA, Howard VJ. Differences in the role of black race and stroke risk factors for frst vs. recurrent stroke. Neurology. 2016;86:637-642. doi: 10.1212/WNL.0000000000002376.
62. Seshadri S, Beiser A, Pikula A, Himali JJ, Kelly-Hayes M, Debette S, DeStefano AL, Romero JR, Kase CS, Wolf PA. Parental occurrence of stroke and risk of stroke in their children: the Framingham study. Circulation. 2010;121:1304-1312. doi: 10.1161/CIRCULATIONAHA.109.854240.
63. Schulz UG, Flossmann E, Rothwell PM. Heritability of ischemic stroke in relation to age, vascular risk factors, and subtypes of incident stroke in population-based studies. Stroke. 2004;35:819-824. doi: 10.1161/01. STR.0000121646.23955.0f.
64. Touzé E, Rothwell PM. Sex differences in heritability of ischemic stroke: a systematic review and meta-analysis. Stroke. 2008;39:16-23. doi: 10.1161/STROKEAHA.107.484618.
65. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572. doi: 10.1001/jama.289.19.2560.
66. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specifc relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
67. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
68. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287:1003-1010.
69. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004;44:398-404. doi: 10.1161/01. HYP.0000142248.54761.56.
70. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:2043-2050. doi: 10.1001/jama.2010.650.
71. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic signifcance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895-905. doi: 10.1016/S0140-6736(10)60308-X.
72. Suchy-Dicey AM, Wallace ER, Mitchell SV, Aguilar M, Gottesman RF, Rice K, Kronmal R, Psaty BM, Longstreth WT Jr. Blood pressure variability and the risk of all-cause mortality, incident myocardial infarction, and incident stroke in the cardiovascular health study. Am J Hypertens. 2013;26:1210-1217. doi: 10.1093/ajh/hpt092.
73. Banerjee C, Moon YP, Paik MC, Rundek T, Mora-McLaughlin C, Vieira JR, Sacco RL, Elkind MS. Duration of diabetes and risk of ischemic stroke: the Northern Manhattan Study. Stroke. 2012;43:1212-1217. doi: 10.1161/STROKEAHA.111.641381.
74. Sui X, Lavie CJ, Hooker SP, Lee DC, Colabianchi N, Lee CD, Blair SN. A prospective study of fasting plasma glucose and risk of stroke in asymptomatic men. Mayo Clin Proc. 2011;86:1042-1049. doi: 10.4065/mcp.2011.0267.
75. Utsumi H, Elkind MM. Potentially lethal damage, defcient repair in X-ray-sensitive caffeine-responsive Chinese hamster cells. Radiat Res. 1986;107:95-106.
76. Kissela BM, Khoury J, Kleindorfer D, Woo D, Schneider A, Alwell K, Miller R, Ewing I, Moomaw CJ, Szafarski JP, Gebel J, Shukla R, Broderick J P. Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati/Northern Kentucky Stroke Study. Diabetes Care. 2005;28:355-359.
77. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a mul-tifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-591. doi: 10.1056/NEJMoa0706245.
78. Anselmino M, Malmberg K, Ohrvik J, Rydén L; Euro Heart Survey Investigators. Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur J Cardiovasc Prev Rehabil. 2008;15:216-223. doi: 10.1097/HJR.0b013e3282f335d0.
79. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589. doi: 10.1056/NEJMoa0806470.
80. Gray CS, Hildreth AJ, Sandercock PA, O'Connell JE, Johnston DE, Cartlidge NE, Bamford JM, James OF, Alberti KG; GIST Trialists Collaboration. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol. 2007;6:397-406. doi: 10.1016/S1474-4422(07)70080-7.
81. Yiin GS, Howard DP, Paul NL, Li L, Luengo-Fernandez R, Bull LM, Welch SJ, Gutnikov SA, Mehta Z, Rothwell PM; Oxford Vascular Study. Age-specifc incidence, outcome, cost, and projected future burden of atrial fbrillation-related embolic vascular events: a population-based study. Circulation. 2014;130:1236-1244. doi: 10.1161/CIRCULATIONAHA.114.010942.
82. Brambatti M, Connolly SJ, Gold MR, et al; ASSERT Investigators. Temporal relationship between subclinical atrial fbrillation and embolic events. Circulation. 2014;129:2094-2099. doi: 10.1161/CIRCULATIONAHA.113.007825.
83. Kamel H, Elkind MS, Bhave PD, Navi BB, Okin PM, Iadecola C, Devereux RB, Fink ME. Paroxysmal supraventricular tachycardia and the risk of ischemic stroke. Stroke. 2013;44:1550-1554. doi: 10.1161/STROKEAHA.113.001118.
84. Disertori M, Quintarelli S, Grasso M, et al. Autosomal recessive atrial dilated cardiomyopathy with standstill evolution associated with mutation of Natriuretic Peptide Precursor A. Circ Cardiovasc Genet. 2013;6:27-36. doi: 10.1161/CIRCGENETICS.112.963520.
85. O'Neal WT, Kamel H, Kleindorfer D, Judd SE, Howard G, Howard VJ, Soliman EZ. Premature atrial contractions on the screening electrocardiogram and risk of ischemic stroke: the Reasons for Geographic and Racial Differences in Stroke study. Neuroepidemiology. 2016;47:53-58. doi: 10.1159/000448619.
86. Kamel H, Hunter M, Moon YP, Yaghi S, Cheung K, Di Tullio MR, Okin PM, Sacco RL, Soliman EZ, Elkind MS. Electrocardiographic left atrial abnormality and risk of stroke: Northern Manhattan Study. Stroke. 2015;46:3208-3212. doi: 10.1161/STROKEAHA.115.009989.
87. Kamel H, O'Neal WT, Okin PM, Loehr LR, Alonso A, Soliman EZ. Electrocardiographic left atrial abnormality and stroke subtype in the atherosclerosis risk in communities study. Ann Neurol. 2015;78:670-678. doi: 10.1002/ana.24482.
88. Okin PM, Kamel H, Kjeldsen SE, Devereux RB. Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive pa-tients with electrocardiographic left ventricular hypertrophy. J Hypertens. 2016;34:1831-1837. doi: 10.1097/HJH.0000000000000989.
89. Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fbrillation and mechanisms of stroke: time for a new model. Stroke. 2016;47:895-900. doi: 10.1161/STROKEAHA.115.012004.
90. Longstreth WT Jr, Kronmal RA, Thompson JL, Christenson RH, Levine SR, Gross R, Brey RL, Buchsbaum R, Elkind MS, Tirschwell DL, Seliger SL, Mohr JP, deFilippi CR. Amino terminal pro-B-type natriuretic pep-tide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke. 2013;44:714-719. doi: 10.1161/STROKEAHA.112.675942.
91. Horenstein RB, Smith DE, Mosca L. Cholesterol predicts stroke mortality in the Women's Pooling Project. Stroke. 2002;33:1863-1868.
92. Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, Gaziano JM. Lipid levels and the risk of ischemic stroke in women. Neurology. 2007;68:556-562. doi: 10.1212/01.wnl.0000254472.41810.0d.
93. Lindenstrøm E, Boysen G, Nyboe J. Infuence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascu-lar disease: the Copenhagen City Heart Study. BMJ. 1994;309:11-15.
94. Soyama Y, Miura K, Morikawa Y, Nishijo M, Nakanishi Y, Naruse Y, Kagamimori S, Nakagawa H; Oyabe Study. High-density lipo-protein cholesterol and risk of stroke in Japanese men and women: the Oyabe Study. Stroke. 2003;34:863-868. doi: 10.1161/01. STR.0000060869.34009.38.
95. Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. Stroke. 1997;28:83-87.
96. Wannamethee SG, Shaper AG, Ebrahim S. HDL-cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke. 2000;31:1882-1888.
97. Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin IF, Cheng JF, Paik MC, Shea S, Berglund L. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA. 2001;285:2729-2735.
98. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350, 977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320:904-910. doi: 10.1056/NEJM198904063201405.
99. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, MacMahon S, Woodward M; Asia Pacifc Cohort Studies Collaboration. Cholesterol, coronary heart disease, and stroke in the Asia Pacifc region. Int J Epidemiol. 2003;32:563-572.
100. Iribarren C, Jacobs DR, Sadler M, Claxton AJ, Sidney S. Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confned to elderly men? The Kaiser Permanente Medical Care Program. Stroke. 1996;27:1993-1998.
101. Hackam DG, Austin PC, Huang A, Juurlink DN, Mamdani MM, Paterson JM, Hachinski V, Li P, Kapral MK. Statins and intracerebral hemorrhage: a retrospective cohort study. Arch Neurol. 2012;69:39-45. doi: 10.1001/archneurol.2011.228.
102. Amarenco P, Labreuche J, Lavallée P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902-2909. doi: 10.1161/01. STR.0000147965.52712.fa.
103. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Effcacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278. doi: 10.1016/S0140-6736(05)67394-1.
104. Lauer A, Greenberg SM, Gurol ME. Statins in intracerebral hemorrhage. Curr Atheroscler Rep. 2015;17:46. doi: 10.1007/s11883-015-0526-5.
105. Goldstein LB, Amarenco P, Szarek M, Callahan A 3rd, Hennerici M, Sillesen H, Zivin JA, Welch KM; SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008;70:2364-2370. doi: 10.1212/01. wnl.0000296277.63350.77.
106. Zhou ML, Zhu L, Wang J, Hang CH, Shi JX. The infammation in the gut after experimental subarachnoid hemorrhage. J Surg Res. 2007;137:103-108. doi: 10.1016/j.jss.2006.06.023.
107. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151:1141-1147.
108. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM; American Heart Association. Dietary approaches to prevent and treat hypertension: a scientifc statement from the American Heart Association. Hypertension. 2006;47:296-308. doi: 10.1161/01. HYP.0000202568.01167.B6.
109. Appel LJ, Angell SY, Cobb LK, Limper HM, Nelson DE, Samet JM, Brownson RC. Population-wide sodium reduction: the bumpy road from evidence to policy. Ann Epidemiol. 2012;22:417-425. doi: 10.1016/j. annepidem.2012.04.003.
110. Perry IJ, Beevers DG. Salt intake and stroke: a possible direct effect. J Hum Hypertens. 1992;6:23-25.
111. He J, Ogden LG, Vupputuri S, Bazzano LA, Loria C, Whelton PK. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA. 1999;282:2027-2034.
112. Nagata C, Takatsuka N, Shimizu N, Shimizu H. Sodium intake and risk of death from stroke in Japanese men and women. Stroke. 2004;35:1543-1547. doi: 10.1161/01.STR.0000130425.50441.b0.
113. Li XY, Cai XL, Bian PD, Hu LR. High salt intake and stroke: meta-anal-ysis of the epidemiologic evidence. CNS Neurosci Ther. 2012;18:691-701. doi: 10.1111/j.1755-5949.2012.00355.x.
114. Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ. 2009;339:b4567.
115. Ascherio A, Rimm EB, Hernán MA, Giovannucci EL, Kawachi I, Stampfer MJ, Willett WC. Intake of potassium, magnesium, calcium, and fber and risk of stroke among US men. Circulation. 1998;98:1198-1204.
116. Khaw KT, Barrett-Connor E. Dietary potassium and stroke-associated mortality. A 12-year prospective population study. N Engl J Med. 1987;316:235-240. doi: 10.1056/NEJM198701293160502.
117. D'Elia L, Barba G, Cappuccio FP, Strazzullo P. Potassium intake, stroke, and cardiovascular disease a meta-analysis of prospective studies. J Am Coll Cardiol. 2011;57:1210-1219. doi: 10.1016/j.jacc.2010.09.070.
118. Larsson SC, Orsini N, Wolk A. Dietary potassium intake and risk of stroke: a dose-response meta-analysis of prospective studies. Stroke. 2011;42:2746-2750. doi: 10.1161/STROKEAHA.111.622142.
119. Estruch R, Ros E, Salas-Salvadó J, et al; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279-1290. doi: 10.1056/NEJMoa1200303.
120. He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. Lancet. 2006;367:320-326. doi: 10.1016/S0140-6736(06)68069-0.
121. Suk SH, Sacco RL, Boden-Albala B, Cheun JF, Pittman JG, Elkind MS, Paik MC; Northern Manhattan Stroke Study. Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke. 2003;34:1586-1592. doi: 10.1161/01.STR.0000075294.98582.2F.
122. Walker SP, Rimm EB, Ascherio A, Kawachi I, Stampfer MJ, Willett WC. Body size and fat distribution as predictors of stroke among US men. Am J Epidemiol. 1996;144:1143-1150.
123. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects), Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet. 2014;383:970-983. doi: 10.1016/S0140-6736(13)61836-X.
124. Arenillas JF, Moro MA, Dávalos A. The metabolic syndrome and stroke: potential treatment approaches. Stroke. 2007;38:2196-2203. doi: 10.1161/STROKEAHA.106.480004.
125. Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke. 2005;36:1366-1371. doi: 10.1161/01.STR.0000169945.75911.33.
126. Najarian RM, Sullivan LM, Kannel WB, Wilson PW, D'Agostino RB, Wolf PA. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med. 2006;166:106-111. doi: 10.1001/archinte.166.1.106.
127. Kuo SH, Lee YT, Li CR, Tseng CJ, Chao WN, Wang PH, Wong RH, Chen CC, Chen SC, Lee MC. Mortality in emergency department sepsis score as a prognostic indicator in patients with pyogenic liver abscess. Am J Emerg Med. 2013;31:916-921. doi: 10.1016/j.ajem.2013.02.045.
128. Gill JS, Zezulka AV, Shipley MJ, Gill SK, Beevers DG. Stroke and al-cohol consumption. N Engl J Med. 1986;315:1041-1046. doi: 10.1056/NEJM198610233151701.
129. Hillbom M, Numminen H, Juvela S. Recent heavy drinking of alcohol and embolic stroke. Stroke. 1999;30:2307-2312.
130. Klatsky AL, Armstrong MA, Friedman GD, Sidney S. Alcohol drinking and risk of hospitalization for ischemic stroke. Am J Cardiol. 2001;88:703-706.
131. Mazzaglia G, Britton AR, Altmann DR, Chenet L. Exploring the relationship between alcohol consumption and non-fatal or fatal stroke: a systematic review. Addiction. 2001;96:1743-1756. doi: 10.1080/09652140120089490.
132. Wannamethee SG, Shaper AG. Patterns of alcohol intake and risk of stroke in middle-aged British men. Stroke. 1996;27:1033-1039.
133. Rantakömi SH, Laukkanen JA, Sivenius J, Kauhanen J, Kurl S. Alcohol consumption and the risk of stroke among hypertensive and overweight men. J Neurol. 2013;260:534-539. doi: 10.1007/s00415-012-6672-6.
134. Hillbom M, Saloheimo P, Juvela S. Alcohol consumption, blood pres-sure, and the risk of stroke. Curr Hypertens Rep. 2011;13:208-213. doi: 10.1007/s11906-011-0194-y.
135. Judd SE, McClure LA, Howard VJ, Lackland DT, Halanych JH, Kabagambe EK. Heavy drinking is associated with poor blood pressure control in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Int J Environ Res Public Health. 2011;8:1601-1612. doi: 10.3390/ijerph8051601.
136. Wakabayashi I, Araki Y. Infuences of gender and age on relationships between alcohol drinking and atherosclerotic risk factors. Alcohol Clin Exp Res. 2010;34(suppl 1):S54-S60. doi: 10.1111/j.1530-0277.2008.00758.x.
137. Foerster M, Marques-Vidal P, Gmel G, Daeppen JB, Cornuz J, Hayoz D, Pécoud A, Mooser V, Waeber G, Vollenweider P, Paccaud F, Rodondi N. Alcohol drinking and cardiovascular risk in a population with high mean alcohol consumption. Am J Cardiol. 2009;103:361-368. doi: 10.1016/j. amjcard.2008.09.089.
138. Ohira T, Tanigawa T, Tabata M, Imano H, Kitamura A, Kiyama M, Sato S, Okamura T, Cui R, Koike KA, Shimamoto T, Iso H. Effects of habitual alcohol intake on ambulatory blood pressure, heart rate, and its variability among Japanese men. Hypertension. 2009;53:13-19. doi: 10.1161/HYPERTENSIONAHA.108.114835.
139. Taylor B, Irving HM, Baliunas D, Roerecke M, Patra J, Mohapatra S, Rehm J. Alcohol and hypertension: gender differences in dose-response relationships determined through systematic review and meta-analysis. Addiction. 2009;104:1981-1990. doi: 10.1111/j.1360-0443.2009.02694.x.
140. Brust JC. Neurological Aspects of Substance Abuse. Philadelphia, PA: Butterworth-Heinemann; 2004.
141. Esse K, Fossati-Bellani M, Traylor A, Martin-Schild S. Epidemic of il-licit drug use, mechanisms of action/addiction and stroke as a health hazard. Brain Behav. 2011;1:44-54. doi: 10.1002/brb3.7.
142. Ho EL, Josephson SA, Lee HS, Smith WS. Cerebrovascular complications of methamphetamine abuse. Neurocrit Care. 2009;10:295-305. doi: 10.1007/s12028-008-9177-5.
143. Bhat VM, Cole JW, Sorkin JD, Wozniak MA, Malarcher AM, Giles WH, Stern BJ, Kittner SJ. Dose-response relationship between cigarette smoking and risk of ischemic stroke in young women. Stroke. 2008;39:2439-2443. doi: 10.1161/STROKEAHA.107.510073.
144. Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA. 2000;284:706-712.
145. Burns DM. Epidemiology of smoking-induced cardiovascular disease. Prog Cardiovasc Dis. 2003;46:11-29.
146. Fagerström K. The epidemiology of smoking: health consequences and benefts of cessation. Drugs. 2002;62(suppl 2):1-9.
147. Robbins AS, Manson JE, Lee IM, Satterfeld S, Hennekens CH. Cigarette smoking and stroke in a cohort of U.S. male physicians. Ann Intern Med. 1994;120:458-462.
148. Song YM, Cho HJ. Risk of stroke and myocardial infarction after reduction or cessation of cigarette smoking: a cohort study in korean men. Stroke. 2008;39:2432-2438. doi: 10.1161/STROKEAHA.107.512632.
149. Malek AM, Cushman M, Lackland DT, Howard G, McClure LA. Secondhand smoke exposure and stroke: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Am J Prev Med. 2015;49:e89-e97. doi: 10.1016/j.amepre.2015.04.014.
150. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J; Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132-140. doi: 10.1016/S0140-6736(09)61717-7.
151. Zhou Y, Han W, Gong D, Man C, Fan Y. Hs-CRP in stroke: a meta-anal-ysis. Clin Chim Acta. 2016;453:21-27. doi: 10.1016/j.cca.2015.11.027.
152. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897-1908. doi: 10.1056/NEJMoa0707402.
153. Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, Bassler N, Qian H, von Zur Muhlen C, Hagemeyer CE, Ahrens I, Chin-Dusting J, Bobik A, Peter K. Dissociation of pentameric to mo-nomeric C-reactive protein on activated platelets localizes infammation to atherosclerotic plaques. Circ Res. 2009;105:128-137. doi: 10.1161/CIRCRESAHA.108.190611.
154. Thompson D, Pepys MB, Wood SP. The physiological structure of hu-man C-reactive protein and its complex with phosphocholine. Structure. 1999;7:169-177. doi: 10.1016/S0969-2126(99)80023-9.
155. Fujita Y, Yamaguchi S, Kakino A, Iwamoto S, Yoshimoto R, Sawamura T. Lectin-like oxidized LDL receptor 1 is involved in CRP-mediated complement activation. Clin Chem. 2011;57:1398-1405. doi: 10.1373/clinchem.2011.168625.
156. Libby P. Infammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045-2051. doi: 10.1161/ATVBAHA.108.179705.
157. Elkind MS, Ramakrishnan P, Moon YP, Boden-Albala B, Liu KM, Spitalnik SL, Rundek T, Sacco RL, Paik MC. Infectious burden and risk of stroke: the northern Manhattan study. Arch Neurol. 2010;67:33-38. doi: 10.1001/archneurol.2009.271.
158. Elkind MS, Luna JM, Moon YP, Boden-Albala B, Liu KM, Spitalnik S, Rundek T, Sacco RL, Paik MC. Infectious burden and carotid plaque thickness: the northern Manhattan study. Stroke. 2010;41:e117-e122. doi: 10.1161/STROKEAHA.109.571299.
159. Wright CB, Gardener H, Dong C, Yoshita M, DeCarli C, Sacco RL, Stern Y, Elkind MS. Infectious burden and cognitive decline in the Northern Manhattan Study. J Am Geriatr Soc. 2015;63:1540-1545. doi: 10.1111/jgs.13557.
160. Katan M, Moon YP, Paik MC, Sacco RL, Wright CB, Elkind MS. Infectious burden and cognitive function: the Northern Manhattan Study. Neurology. 2013;80:1209-1215. doi: 10.1212/WNL.0b013e3182896e79.
161. Ovbiagele B, Nath A. Increasing incidence of ischemic stroke in pa-tients with HIV infection. Neurology. 2011;76:444-450. doi: 10.1212/WNL.0b013e31820a0cfc.
162. Chow FC, He W, Bacchetti P, Regan S, Feske SK, Meigs JB, Grinspoon SK, Triant VA. Elevated rates of intracerebral hemorrhage in individuals from a US clinical care HIV cohort. Neurology. 2014;83:1705-1711. doi: 10.1212/WNL.0000000000000958.
163. Gutierrez J, Goldman J, Dwork AJ, Elkind MS, Marshall RS, Morgello S. Brain arterial remodeling contribution to nonembolic brain infarcts in patients with HIV. Neurology. 2015;85:1139-1145. doi: 10.1212/WNL.0000000000001976.
164. Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J; D:A:D Study Group. Associations between immune depression and cardiovascular events in HIV infection. AIDS. 2013;27:2735-2748. doi: 10.1097/01.aids.0000432457.91228.f3.
165. Gutierrez J, Elkind MS, Marshall RS. Cardiovascular profle and events of US adults 20-49 years with HIV: results from the NHANES 1999-2008. AIDS Care. 2013;25:1385-1391. doi: 10.1080/09540121.2013.769493.
166. Elkind MS, Carty CL, O'Meara ES, Lumley T, Lefkowitz D, Kronmal RA, Longstreth WT Jr. Hospitalization for infection and risk of acute ischemic stroke: the Cardiovascular Health Study. Stroke. 2011;42:1851-1856. doi: 10.1161/STROKEAHA.110.608588.
167. Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Infuenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015;5:CD005050.
168. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611-2618. doi: 10.1056/NEJMoa041747.
169. Walkey AJ, Hammill BG, Curtis LH, Benjamin EJ. Long-term outcomes following development of new-onset atrial fbrillation during sepsis. Chest. 2014;146:1187-1195. doi: 10.1378/chest.14-0003.
170. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, Newman A, Loehr L, Folsom AR, Elkind MS, Lyles MF, Kronmal RA, Yende S. Association between hospitalization for pneumo-nia and subsequent risk of cardiovascular disease. JAMA. 2015;313:264-274. doi: 10.1001/jama.2014.18229.
171. Corrales-Medina VF, Taljaard M, Yende S, Kronmal R, Dwivedi G, Newman AB, Elkind MS, Lyles MF, Chirinos JA. Intermediate and long-term risk of new-onset heart failure after hospitalization for pneumonia in elderly adults. Am Heart J. 2015;170:306-312. doi: 10.1016/j. ahj.2015.04.028.
172. Dalager-Pedersen M, Søgaard M, Schønheyder HC, Nielsen H, Thomsen RW. Risk for myocardial infarction and stroke after community-acquired bacteremia: a 20-year population-based cohort study. Circulation. 2014;129:1387-1396. doi: 10.1161/CIRCULATIONAHA.113.006699.
173. Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J. 2008;29:96-103. doi: 10.1093/eurheartj/ehm516.
174. Tonne C, Halonen JI, Beevers SD, Dajnak D, Gulliver J, Kelly FJ, Wilkinson P, Anderson HR. Long-term traffc air and noise pollution in relation to mortality and hospital readmission among myocardial infarction survivors. Int J Hyg Environ Health. 2016;219:72-78. doi: 10.1016/j.ijheh.2015.09.003.
175. Mostofsky E, Schwartz J, Coull BA, Koutrakis P, Wellenius GA, Suh HH, Gold DR, Mittleman MA. Modeling the association between particle constituents of air pollution and health outcomes. Am J Epidemiol. 2012;176:317-326. doi: 10.1093/aje/kws018.
176. O'Donnell MJ, Fang J, Mittleman MA, Kapral MK, Wellenius GA; Investigators of the Registry of Canadian Stroke Network. Fine particulate air pollution (PM2.5) and the risk of acute ischemic stroke. Epidemiology. 2011;22:422-431. doi: 10.1097/EDE.0b013e3182126580.
177. Suissa L, Fortier M, Lachaud S, Staccini P, Mahagne MH. Ozone air pollution and ischaemic stroke occurrence: a case-crossover study in Nice, France. BMJ Open. 2013;3:e004060. doi: 10.1136/bmjopen-2013-004060.
178. Wellenius GA, Schwartz J, Mittleman MA. Air pollution and hospital admissions for ischemic and hemorrhagic stroke among medicare benefciaries. Stroke. 2005;36:2549-2553. doi: 10.1161/01. STR.0000189687.78760.47.
179. Johnson JY, Rowe BH, Villeneuve PJ. Ecological analysis of long-term exposure to ambient air pollution and the incidence of stroke in Edmonton, Alberta, Canada. Stroke. 2010;41:1319-1325. doi: 10.1161/STROKEAHA.110.580571.
180. Chen R, Zhang Y, Yang C, Zhao Z, Xu X, Kan H. Acute effect of ambient air pollution on stroke mortality in the China air pollution and health effects study. Stroke. 2013;44:954-960. doi: 10.1161/STROKEAHA.111.673442.
181. Sørensen M, Lühdorf P, Ketzel M, Andersen ZJ, Tjønneland A, Overvad K, Raaschou-Nielsen O. Combined effects of road traffc noise and ambi-ent air pollution in relation to risk for stroke? Environ Res. 2014;133:49-55. doi: 10.1016/j.envres.2014.05.011.
182. Maheswaran R, Pearson T, Smeeton NC, Beevers SD, Campbell MJ, Wolfe CD. Outdoor air pollution and incidence of ischemic and hemor-rhagic stroke: a small-area level ecological study. Stroke. 2012;43:22-27. doi: 10.1161/STROKEAHA.110.610238.
183. Wing JJ, Adar SD, Sánchez BN, Morgenstern LB, Smith MA, Lisabeth LD. Ethnic differences in ambient air pollution and risk of acute ischemic stroke. Environ Res. 2015;143:62-67. doi: 10.1016/j.envres.2015.09.031.
184. Scheers H, Jacobs L, Casas L, Nemery B, Nawrot TS. Long-term exposure to particulate matter air pollution is a risk factor for stroke: meta-analytical evidence. Stroke. 2015;46:3058-3066. doi: 10.1161/STROKEAHA.115.009913.
185. Matarin M, Brown WM, Singleton A, Hardy JA, Meschia JF; ISGS in-vestigators. Whole genome analyses suggest ischemic stroke and heart disease share an association with polymorphisms on chromosome 9p21. Stroke. 2008;39:1586-1589. doi: 10.1161/STROKEAHA.107.502963.
186. Gretarsdottir S, Thorleifsson G, Manolescu A, et al. Risk variants for atrial fbrillation on chromosome 4q25 associate with ischemic stroke. Ann Neurol. 2008;64:402-409. doi: 10.1002/ana.21480.
187. Bevan S, Traylor M, Adib-Samii P, Malik R, Paul NL, Jackson C, Farrall M, Rothwell PM, Sudlow C, Dichgans M, Markus HS. Genetic heritabil-ity of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations. Stroke. 2012;43:3161-3167. doi: 10.1161/STROKEAHA.112.665760.
188. Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke. 2004;35:212-227. doi: 10.1161/01.STR.0000107187.84390.AA.
189. Carmelli D, DeCarli C, Swan GE, Jack LM, Reed T, Wolf PA, Miller BL. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke. 1998;29:1177-1181.
190. Tournier-Lasserve E, Iba-Zizen MT, Romero N, Bousser MG. Autosomal dominant syndrome with strokelike episodes and leukoencephalopathy. Stroke. 1991;22:1297-1302.
191. Peters N, Opherk C, Bergmann T, Castro M, Herzog J, Dichgans M. Spectrum of mutations in biopsy-proven CADASIL: implications for diagnostic strategies. Arch Neurol. 2005;62:1091-1094. doi: 10.1001/archneur.62.7.1091.
192. Joutel A, Andreux F, Gaulis S, Domenga V, Cecillon M, Battail N, Piga N, Chapon F, Godfrain C, Tournier-Lasserve E. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest. 2000;105:597-605. doi: 10.1172/JCI8047.
193. Ebke M, Dichgans M, Bergmann M, Voelter HU, Rieger P, Gasser T, Schwendemann G. CADASIL: skin biopsy allows diagnosis in early stages. Acta Neurol Scand. 1997;95:351-357.
194. Menezes Cordeiro I, Nzwalo H, Sá F, Ferreira RB, Alonso I, Afonso L, Basílio C. Shifting the CARASIL paradigm: report of a non-Asian family and literature review. Stroke. 2015;46:1110-1112. doi: 10.1161/STROKEAHA.114.006735.
195. Hara K, Shiga A, Fukutake T, et al. Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med. 2009;360:1729-1739. doi: 10.1056/NEJMoa0801560.
196. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci. 2003;116:217-224.
197. Coucke PJ, Willaert A, Wessels MW, et al. Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet. 2006;38:452-457. doi: 10.1038/ng1764.
198. Levy E, Jaskolski M, Grubb A. The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain Pathol. 2006;16:60-70.
199. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288-294.
200. Russell MO, Goldberg HI, Hodson A, Kim HC, Halus J, Reivich M, Schwartz E. Effect of transfusion therapy on arteriographic abnor-malities and on recurrence of stroke in sickle cell disease. Blood. 1984;63:162-169.
201. Schatz J, Brown RT, Pascual JM, Hsu L, DeBaun MR. Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology. 2001;56:1109-1111.
202. Dichgans M. Genetics of ischaemic stroke. Lancet Neurol. 2007;6:149-161. doi: 10.1016/S1474-4422(07)70028-5.
203. Mehta A, Ginsberg L; FOS Investigators. Natural history of the cere-brovascular complications of Fabry disease. Acta Paediatr Suppl. 2005;94:24-27; discussion 29.
204. Martínez-Fernández E, Gil-Peralta A, García-Lozano R, Chinchón I, Aguilera I, Fernández-López O, Arenas J, Campos Y, Bautista J. Mitochondrial disease and stroke. Stroke. 2001;32:2507-2510.
205. Gould DB, Phalan FC, van Mil SE, Sundberg JP, Vahedi K, Massin P, Bousser MG, Heutink P, Miner JH, Tournier-Lasserve E, John SW. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med. 2006;354:1489-1496. doi: 10.1056/NEJMoa053727.
206. Lanfranconi S, Markus HS. COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review. Stroke. 2010;41:e513-e518. doi: 10.1161/STROKEAHA.110.581918.
207. Milewicz DM, Østergaard JR, Ala-Kokko LM, Khan N, Grange DK, Mendoza-Londono R, Bradley TJ, Olney AH, Adès L, Maher JF, Guo D, Buja LM, Kim D, Hyland JC, Regalado ES. De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction. Am J Med Genet A. 2010;152A:2437-2443. doi: 10.1002/ajmg.a.33657.
208. Disabella E, Grasso M, Gambarin FI, Narula N, Dore R, Favalli V, Serio A, Antoniazzi E, Mosconi M, Pasotti M, Odero A, Arbustini E. Risk of dissection in thoracic aneurysms associated with mutations of smooth muscle alpha-actin 2 (ACTA2). Heart. 2011;97:321-326. doi: 10.1136/hrt.2010.204388.
209. Munot P, Saunders DE, Milewicz DM, Regalado ES, Ostergaard JR, Braun KP, Kerr T, Lichtenbelt KD, Philip S, Rittey C, Jacques TS, Cox TC, Ganesan V. A novel distinctive cerebrovascular phenotype is associated with heterozygous Arg179 ACTA2 mutations. Brain. 2012;135:2506-2514. doi: 10.1093/brain/aws172.
210. Williams FM, Carter AM, Hysi PG, et al; EuroCLOT Investigators; Wellcome Trust Case Control Consortium 2; MOnica Risk, Genetics, Archiving and Monograph; MetaStroke; International Stroke Genetics Consortium. Ischemic stroke is associated with the ABO locus: the EuroCLOT study. Ann Neurol. 2013;73:16-31. doi: 10.1002/ana.23838.
211. Network NSG, International Stroke Genetics C. Loci associated with ischaemic stroke and its subtypes (sign): a genome-wide association study [published online ahead of print December 18, 2015]. Lancet Neurol. doi: 10.1016/S1474-4422(15)00338-5.
212. Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium; Stroke Genetics Network (SiGN); International Stroke Genetics Consortium (ISGC). Identifcation of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2016;15:695-707. doi: 10.1016/S1474-4422(16)00102-2.
213. French CR, Seshadri S, Destefano AL, et al. Mutation of FOXC1 and PITX2 induces cerebral small-vessel disease. J Clin Invest. 2014;124:4877-4881. doi: 10.1172/JCI75109.
214. Malik R, Traylor M, Pulit SL, et al; ISGC Analysis Group; METASTROKE collaboration; Wellcome Trust Case Control Consortium 2 (WTCCC2); NINDS Stroke Genetics Network (SiGN). Low-frequency and common genetic variation in ischemic stroke: The METASTROKE collaboration. Neurology. 2016;86:1217-1226. doi: 10.1212/WNL.0000000000002528.
215. Erdmann J, Stark K, Esslinger UB, et al; CARDIoGRAM. Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature. 2013;504:432-436. doi: 10.1038/nature12722.
216. Schunkert H, Götz A, Braund P, et al; Cardiogenics Consortium. Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation. 2008;117:1675-1684. doi: 10.1161/CIRCULATIONAHA.107.730614.
217. Gschwendtner A, Bevan S, Cole JW, et al; International Stroke Genetics Consortium. Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke. Ann Neurol. 2009;65:531-539. doi: 10.1002/ana.21590.
218. Weintraub WS, Daniels SR, Burke LE, Franklin BA, Goff DC Jr, Hayman LL, Lloyd-Jones D, Pandey DK, Sanchez EJ, Schram AP, Whitsel LP; American Heart Association Advocacy Coordinating Committee; Council on Cardiovascular Disease in the Young; Council on the Kidney in Cardiovascular Disease; Council on Epidemiology and Prevention; Council on Cardiovascular Nursing; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Clinical Cardiology, and Stroke Council. Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. Circulation. 2011;124:967-990. doi: 10.1161/CIR.0b013e3182285a81.
219. Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160-2236. doi: 10.1161/STR.0000000000000024.
220. Howard VJ, McDonnell MN. Physical activity in primary stroke prevention: just do it! Stroke. 2015;46:1735-1739. doi: 10.1161/STROKEAHA.115.006317.
221. Marcus BH, Williams DM, Dubbert PM, Sallis JF, King AC, Yancey AK, Franklin BA, Buchner D, Daniels SR, Claytor RP; American Heart Association Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity); American Heart Association Council on Cardiovascular Disease in the Young; Interdisciplinary Working Group on Quality of Care and Outcomes Research. Physical activity intervention studies: what we know and what we need to know: a scientifc statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity); Council on Cardiovascular Disease in the Young; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. Circulation. 2006;114:2739-2752. doi: 10.1161/CIRCULATIONAHA.106.179683.
222. Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, Veerman JL, Delwiche K, Iannarone ML, Moyer ML, Cercy K, Vos T, Murray CJ, Forouzanfar MH. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. BMJ. 2016;354:i3857.
223. Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, Sigamani A, Mohan V, Gupta R, Thomas N; Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373:1341-1351. doi: 10.1016/S0140-6736(09)60611-5.
224. Yusuf S, Islam S, Chow CK, et al; Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378:1231-1243. doi: 10.1016/S0140-6736(11)61215-4.
225. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ. 2002;324:1570-1576.
226. Yusuf S, Bosch J, Dagenais G, et al; HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021-2031. doi: 10.1056/NEJMoa1600176.
227. Cushman WC, Goff DC Jr. More HOPE for prevention with statins. N Engl J Med. 2016;374:2085-2087. doi: 10.1056/NEJMe1603504.
228. Yusuf S, Lonn E, Pais P, et al; HOPE-3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med. 2016;374:2032-2043. doi: 10.1056/NEJMoa1600177.
229. Lonn EM, Bosch J, López-Jaramillo P, et al; HOPE-3 Investigators. Blood-Pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009-2020. doi: 10.1056/NEJMoa1600175.
230. Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR Jr, Tudor-Locke C, Greer JL, Vezina J, Whitt-Glover MC, Leon AS. 2011 compendium of physical activities: a second update of codes and MET values. Med Sci Sports Exerc. 2011;43:1575-1581. doi: 10.1249/MSS.0b013e31821ece12.
231. Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. Stroke. 2003;34:2475-2481. doi: 10.1161/01. STR.0000091843.02517.9D.
232. Physical Activity Guidelines Advisory Committee Report, 2008. To the secretary of health and human services. Part a: executive summary. Nutr Rev. 2009;67:114-120.
233. Willey JZ, Moon YP, Paik MC, Boden-Albala B, Sacco RL, Elkind MS. Physical activity and risk of ischemic stroke in the Northern Manhattan Study. Neurology. 2009;73:1774-1779. doi: 10.1212/WNL.0b013e3181c34b58.
234. Eckel RH, Jakicic JM, Ard JD, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovas-cular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S76-S99. doi: 10.1161/01.cir.0000437740.48606.d1.
235. Rees K, Dyakova M, Wilson N, Ward K, Thorogood M, Brunner E. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev. 2013:CD002128.
236. Boden-Albala B, Southwick L, Carman H. Dietary interventions to lower the risk of stroke. Curr Neurol Neurosci Rep. 2015;15:15. doi: 10.1007/s11910-015-0538-0.
237. Fung TT, Stampfer MJ, Manson JE, Rexrode KM, Willett WC, Hu FB. Prospective study of major dietary patterns and stroke risk in women. Stroke. 2004;35:2014-2019. doi: 10.1161/01. STR.0000135762.89154.92.
238. Lakkur S, Judd SE. Diet and stroke: recent evidence supporting a Mediterranean-style diet and food in the primary prevention of stroke. Stroke. 2015;46:2007-2011. doi: 10.1161/STROKEAHA.114.006306.
239. Willett WC, Sacks F, Trichopoulou A, Drescher G, Ferro-Luzzi A, Helsing E, Trichopoulos D. Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr. 1995;61:1402S-1406S.
240. Salehi-Abargouei A, Maghsoudi Z, Shirani F, Azadbakht L. Effects of dietary approaches to stop hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases-incidence: a systematic review and me-ta-analysis on observational prospective studies. Nutrition. 2013;29:611-618. doi: 10.1016/j.nut.2012.12.018.
241. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA. 1988;259:1025-1029.
242. Phs Guideline Update Panel Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U.S. Public health service clinical practice guideline executive summary. Respir Care. 2008;53:1217-1222.
243. Chelladurai Y, Singh S. Varenicline and cardiovascular adverse events: a perspective review. Ther Adv Drug Saf. 2014;5:167-172. doi: 10.1177/2042098614530421.
244. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 ran-domised trials in the context of expectations from prospective epidemio-logical studies. BMJ. 2009;338:b1665.
245. Chen GJ, Yang MS. The effects of calcium channel blockers in the pre-vention of stroke in adults with hypertension: a meta-analysis of data from 273, 543 participants in 31 randomized controlled trials. PLoS One. 2013;8:e57854. doi: 10.1371/journal.pone.0057854.
246. Meschia JF, Bushnell C, Boden-Albala B, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:3754-3832. doi: 10.1161/STR.0000000000000046.
247. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520. doi: 10.1001/jama.2013.284427.
248. Wright JT Jr, Williamson JD, Whelton PK, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103-2116. doi: 10.1056/NEJMoa1511939.
249. Kernan WN, Viscoli CM, Furie KL, et al; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321-1331. doi: 10.1056/NEJMoa1506930.
250. Professional practice committee for the standards of medical care in dia-betes-2016. Diabetes Care. 2016;39(suppl 1):S107-108. doi: 10.2337/dc16-S018.
251. Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2015;75:1071-1094. doi: 10.1007/s40265-015-0416-8.
252. Heart Protection Study Collaborative Group. Mrc/bhf heart protection study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
253. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R; Cholesterol Treatment Trialists' (CTT) Collaboration. Effcacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681. doi: 10.1016/S0140-6736(10)61350-5.
254. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453-463. doi: 10.1016/S1474-4422(09)70058-4.
255. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559. doi: 10.1056/NEJMoa061894.
256. Amarenco P, Benavente O, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, Gilbert S, Rudolph AE, Simunovic L, Zivin JA, Welch KM; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke. 2009;40:1405-1409. doi: 10.1161/STROKEAHA.108.534107.
257. Elkind MS, Sacco RL, MacArthur RB, Fink DJ, Peerschke E, Andrews H, Neils G, Stillman J, Corporan T, Leifer D, Cheung K. The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke. Int J Stroke. 2008;3:210-218. doi: 10.1111/j.1747-4949.2008.00200.x.
258. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207. doi: 10.1056/NEJMoa0807646.
259. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860. doi: 10.1016/S0140-6736(09)60503-1.
260. Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the pri-mary prevention of cardiovascular events: a systematic evidence review for the U.S. preventive services task force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. (Evidence Syntheses, No. 131.). https://www.ncbi.nlm.nih.gov/books/NBK321623/.
261. Bhatt DL, Fox KA, Hacke W, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of athero-thrombotic events. N Engl J Med. 2006;354:1706-1717. doi: 10.1056/NEJMoa060989.
262. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for preven-tion of thromboembolic complications in chronic atrial fbrillation. The copenhagen afasak study. Lancet. 1989;1:175-179.
263. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84:527-539.
264. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atri-al fbrillation. N Engl J Med. 2009;361:1139-1151. doi: 10.1056/NEJMoa0905561.
265. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fbrillation. N Engl J Med. 2011;365:883-891. doi: 10.1056/NEJMoa1009638.
266. Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fbrillation. N Engl J Med. 2013;369:2093-2104. doi: 10.1056/NEJMoa1310907.
267. Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fbrillation. N Engl J Med. 2011;365:981-992. doi: 10.1056/NEJMoa1107039.
268. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specifc oral antico-agulants: a systematic review and meta-analysis. Blood. 2014;124:2450-2458. doi: 10.1182/blood-2014-07-590323.
269. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classifcation schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
270. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refning clinical risk stratifcation for predicting stroke and thromboembolism in atrial fbrillation using a novel risk factor-based approach: the euro heart survey on atrial fbrillation. Chest. 2010;137:263-272. doi: 10.1378/chest.09-1584.
271. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fbrillation. Ann Thorac Surg. 1996;61:755-759. doi: 10.1016/0003-4975(95)00887-X.
272. Bartus K, Han FT, Bednarek J, Myc J, Kapelak B, Sadowski J, Lelakowski J, Bartus S, Yakubov SJ, Lee RJ. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fbril-lation: initial clinical experience. J Am Coll Cardiol. 2013;62:108-118. doi: 10.1016/j.jacc.2012.06.046.
273. Kebernik J, Jose J, Abdel-Wahab M, Stöcker B, Geist V, Richardt G. Safety and eEffcacy of left atrial appendage closure with the amplatzer cardiac plug in very high stroke and bleeding risk patients with nonval-vular atrial fbrillation. Cardiol Ther. 2015;4:167-177. doi: 10.1007/s40119-015-0053-z.
274. Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, Halperin JL, Holmes D; PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fbrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial. Circulation. 2013;127:720-729. doi: 10.1161/CIRCULATIONAHA.112.114389.
275. Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fbrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64:1-12. doi: 10.1016/j.jacc.2014.04.029.
276. Waksman R, Pendyala LK. Overview of the Food and Drug Administration circulatory system devices panel meetings on WATCHMAN left atrial appendage closure therapy. Am J Cardiol. 2015;115:378-384. doi: 10.1016/j.amjcard.2014.11.011.
277. Homma S, Thompson JL, Pullicino PM, et al; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366:1859-1869. doi: 10.1056/NEJMoa1202299.
278. Homma S, Thompson JL, Qian M, et al; WARCEF Investigators. Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy. Circ Heart Fail. 2015;8:504-509. doi: 10.1161/CIRCHEARTFAILURE.114.001725.
279. Lee M, Saver JL, Hong KS, Wu HC, Ovbiagele B. Risk-beneft pro-fle of warfarin versus aspirin in patients with heart failure and sinus rhythm: a meta-analysis. Circ Heart Fail. 2013;6:287-292. doi: 10.1161/CIRCHEARTFAILURE.112.971697.
280. Risk of stroke in the distribution of an asymptomatic carotid artery. The European Carotid Surgery Trialists Collaborative Group. Lancet. 1995;345:209-212.
281. Mohammed N, Anand SS. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomized controlled trial. Mrc asymptomatic carotid surgery trial (ACST) collaborative group. Lancet 2004; 363: 1491-502. Vascular Med. 2005;10:77-78.
282. Rothwell PM. Endarterectomy for symptomatic and asymptomatic carotid stenosis. Neurol Clin. 2008;26:1079-97, x. doi: 10.1016/j.ncl.2008.09.013.
283. Benavente O, Moher D, Pham B. Carotid endarterectomy for asymptomatic carotid stenosis: a meta-analysis. BMJ. 1998;317:1477-1480.
284. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Benefcial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445-453.
285. Raman G, Moorthy D, Hadar N, Dahabreh IJ, O'Donnell TF, Thaler DE, Feldmann E, Lau J, Kitsios GD. Management strategies for asymptomatic carotid stenosis: a systematic review and meta-analysis. Ann Intern Med. 2013;158:676-685. doi: 10.7326/0003-4819-158-9-201305070-00007.
286. Moore WS. Issues to be addressed and hopefully resolved in the carot-id revascularization endarterectomy versus stenting trial 2. Angiology. 2016;67:408-410. doi: 10.1177/0003319715611281.
287. Chimowitz MI, Lynn MJ, Derdeyn CP, et al; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365:993-1003. doi: 10.1056/NEJMoa1105335.
288. Derdeyn CP, Chimowitz MI, Lynn MJ, et al; Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery ste-nosis (SAMMPRIS): the fnal results of a randomised trial. Lancet. 2014;383:333-341. doi: 10.1016/S0140-6736(13)62038-3.